| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 56 | 2023 | 2416 | 3.640 |
Why?
|
| Tissue and Organ Procurement | 25 | 2018 | 987 | 2.650 |
Why?
|
| Kidney Transplantation | 65 | 2016 | 4278 | 2.520 |
Why?
|
| Tissue Donors | 26 | 2018 | 2392 | 1.490 |
Why?
|
| Organ Transplantation | 15 | 2019 | 1172 | 1.380 |
Why?
|
| Living Donors | 15 | 2011 | 647 | 1.350 |
Why?
|
| Lymphoproliferative Disorders | 13 | 2012 | 527 | 1.140 |
Why?
|
| Health Care Rationing | 5 | 2018 | 435 | 1.100 |
Why?
|
| Graft Rejection | 37 | 2013 | 4504 | 0.990 |
Why?
|
| Patient Selection | 10 | 2019 | 4252 | 0.930 |
Why?
|
| Delayed Graft Function | 2 | 2015 | 50 | 0.820 |
Why?
|
| Social Support | 6 | 2019 | 2191 | 0.810 |
Why?
|
| Liver Neoplasms | 12 | 2016 | 4353 | 0.790 |
Why?
|
| Graft Survival | 22 | 2013 | 3904 | 0.750 |
Why?
|
| Transplantation | 3 | 2018 | 222 | 0.750 |
Why?
|
| Waiting Lists | 15 | 2018 | 779 | 0.690 |
Why?
|
| Immunosuppressive Agents | 18 | 2013 | 4215 | 0.670 |
Why?
|
| Death | 5 | 2011 | 685 | 0.660 |
Why?
|
| Tissue and Organ Harvesting | 6 | 2011 | 373 | 0.640 |
Why?
|
| Carcinoma, Hepatocellular | 8 | 2016 | 2326 | 0.630 |
Why?
|
| Psychology | 1 | 2019 | 353 | 0.570 |
Why?
|
| Antilymphocyte Serum | 11 | 2013 | 492 | 0.570 |
Why?
|
| Resource Allocation | 4 | 2018 | 354 | 0.560 |
Why?
|
| Cyclosporine | 7 | 2009 | 778 | 0.550 |
Why?
|
| Tacrolimus | 6 | 2010 | 753 | 0.530 |
Why?
|
| Muromonab-CD3 | 8 | 1998 | 104 | 0.530 |
Why?
|
| Healthcare Disparities | 6 | 2018 | 3411 | 0.520 |
Why?
|
| Transplants | 1 | 2018 | 209 | 0.520 |
Why?
|
| Postoperative Complications | 21 | 2013 | 15831 | 0.500 |
Why?
|
| Kidney Failure, Chronic | 10 | 2013 | 2505 | 0.500 |
Why?
|
| End Stage Liver Disease | 3 | 2018 | 369 | 0.460 |
Why?
|
| Lung Transplantation | 2 | 2013 | 1310 | 0.450 |
Why?
|
| Carbon Monoxide | 3 | 2012 | 560 | 0.430 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2016 | 263 | 0.430 |
Why?
|
| Reperfusion Injury | 4 | 2015 | 1043 | 0.420 |
Why?
|
| Azygos Vein | 1 | 2012 | 19 | 0.410 |
Why?
|
| Goals | 1 | 2017 | 717 | 0.390 |
Why?
|
| Job Satisfaction | 1 | 2016 | 548 | 0.380 |
Why?
|
| Social Adjustment | 2 | 2011 | 634 | 0.380 |
Why?
|
| Acute Kidney Injury | 2 | 2015 | 1946 | 0.360 |
Why?
|
| Geography | 3 | 2017 | 651 | 0.360 |
Why?
|
| Cold Ischemia | 1 | 2011 | 72 | 0.360 |
Why?
|
| Sirolimus | 5 | 2009 | 1540 | 0.340 |
Why?
|
| Occupational Exposure | 1 | 2020 | 1807 | 0.340 |
Why?
|
| Physicians, Family | 1 | 2012 | 348 | 0.340 |
Why?
|
| Workload | 1 | 2016 | 849 | 0.340 |
Why?
|
| Hepatitis B | 2 | 2012 | 709 | 0.330 |
Why?
|
| Patient Rights | 1 | 2010 | 126 | 0.330 |
Why?
|
| Herpesvirus 4, Human | 11 | 1995 | 1080 | 0.330 |
Why?
|
| Hepatectomy | 7 | 2013 | 589 | 0.330 |
Why?
|
| Abdomen | 1 | 2015 | 1137 | 0.320 |
Why?
|
| Decision Making | 2 | 2020 | 3951 | 0.320 |
Why?
|
| Vena Cava, Inferior | 1 | 2012 | 463 | 0.320 |
Why?
|
| Humans | 167 | 2023 | 766766 | 0.320 |
Why?
|
| Medical Futility | 1 | 2010 | 136 | 0.310 |
Why?
|
| Creatinine | 3 | 2011 | 1917 | 0.310 |
Why?
|
| Ethics Committees | 1 | 2008 | 51 | 0.310 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2010 | 186 | 0.310 |
Why?
|
| Pancreas Transplantation | 6 | 2009 | 194 | 0.300 |
Why?
|
| Transplantation Immunology | 5 | 2006 | 540 | 0.300 |
Why?
|
| Hepatitis B virus | 1 | 2012 | 531 | 0.300 |
Why?
|
| Critical Pathways | 1 | 2011 | 475 | 0.300 |
Why?
|
| Informed Consent | 2 | 2011 | 1010 | 0.290 |
Why?
|
| Psychiatry | 1 | 2019 | 1715 | 0.280 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2023 | 157 | 0.270 |
Why?
|
| Family | 4 | 2019 | 3209 | 0.270 |
Why?
|
| Medical Errors | 1 | 2014 | 1260 | 0.260 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2008 | 260 | 0.260 |
Why?
|
| Pancreatic Neoplasms | 3 | 2010 | 5444 | 0.260 |
Why?
|
| Transplantation, Homologous | 16 | 2010 | 4860 | 0.250 |
Why?
|
| Health Services Accessibility | 3 | 2019 | 5514 | 0.250 |
Why?
|
| Kidney | 9 | 2012 | 7074 | 0.250 |
Why?
|
| Intubation | 1 | 2005 | 140 | 0.250 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2010 | 584 | 0.250 |
Why?
|
| Liver | 13 | 2017 | 7571 | 0.240 |
Why?
|
| Physician's Role | 1 | 2012 | 925 | 0.240 |
Why?
|
| Liver Cirrhosis | 5 | 2016 | 1960 | 0.240 |
Why?
|
| Health Status Disparities | 3 | 2018 | 1880 | 0.240 |
Why?
|
| Eligibility Determination | 2 | 2018 | 421 | 0.230 |
Why?
|
| Middle Aged | 76 | 2018 | 223257 | 0.230 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 2171 | 0.230 |
Why?
|
| Male | 88 | 2020 | 364142 | 0.230 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2004 | 29 | 0.220 |
Why?
|
| ABO Blood-Group System | 3 | 2003 | 381 | 0.220 |
Why?
|
| Biliary Fistula | 1 | 2003 | 38 | 0.220 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 2418 | 0.210 |
Why?
|
| Surgical Procedures, Operative | 1 | 2014 | 1931 | 0.210 |
Why?
|
| Female | 94 | 2019 | 396520 | 0.210 |
Why?
|
| Continuity of Patient Care | 2 | 2013 | 1077 | 0.210 |
Why?
|
| Public Policy | 2 | 2017 | 551 | 0.210 |
Why?
|
| Reoperation | 6 | 2012 | 4325 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3110 | 0.200 |
Why?
|
| Tumor Virus Infections | 4 | 2013 | 438 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3232 | 0.200 |
Why?
|
| Alcoholism | 3 | 2023 | 1980 | 0.200 |
Why?
|
| Ultrasonics | 1 | 2003 | 208 | 0.200 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2010 | 996 | 0.200 |
Why?
|
| Adult | 73 | 2018 | 223307 | 0.200 |
Why?
|
| United States | 22 | 2019 | 72951 | 0.190 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2001 | 50 | 0.190 |
Why?
|
| Survival Rate | 10 | 2012 | 12825 | 0.190 |
Why?
|
| Histocompatibility Testing | 7 | 2007 | 726 | 0.180 |
Why?
|
| Prognosis | 20 | 2018 | 29948 | 0.180 |
Why?
|
| Ohio | 5 | 2006 | 320 | 0.180 |
Why?
|
| Surgical Instruments | 1 | 2003 | 379 | 0.180 |
Why?
|
| Liver Diseases | 3 | 2011 | 1303 | 0.180 |
Why?
|
| Liver Regeneration | 2 | 2013 | 213 | 0.180 |
Why?
|
| Device Removal | 1 | 2005 | 643 | 0.180 |
Why?
|
| Hepatic Artery | 2 | 2003 | 233 | 0.170 |
Why?
|
| Rimantadine | 1 | 1999 | 7 | 0.160 |
Why?
|
| Referral and Consultation | 2 | 2010 | 3618 | 0.160 |
Why?
|
| Bile Ducts | 1 | 2000 | 288 | 0.160 |
Why?
|
| Neurilemmoma | 1 | 2004 | 522 | 0.160 |
Why?
|
| Skin Transplantation | 3 | 1992 | 1097 | 0.160 |
Why?
|
| Intestines | 2 | 2005 | 1904 | 0.160 |
Why?
|
| Financial Support | 1 | 2019 | 116 | 0.160 |
Why?
|
| Clinical Competence | 1 | 2014 | 4858 | 0.160 |
Why?
|
| Hospitals, University | 2 | 2009 | 572 | 0.150 |
Why?
|
| Addison Disease | 1 | 1999 | 48 | 0.150 |
Why?
|
| Internet | 2 | 2008 | 3113 | 0.150 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2000 | 236 | 0.150 |
Why?
|
| Friends | 1 | 2019 | 150 | 0.150 |
Why?
|
| Fluconazole | 1 | 1999 | 154 | 0.150 |
Why?
|
| Herpesviridae Infections | 2 | 1995 | 268 | 0.150 |
Why?
|
| Ethics, Medical | 1 | 2023 | 785 | 0.150 |
Why?
|
| Azathioprine | 5 | 2006 | 354 | 0.150 |
Why?
|
| Risk Factors | 19 | 2020 | 74881 | 0.150 |
Why?
|
| Transportation | 1 | 2019 | 217 | 0.150 |
Why?
|
| Hepatitis C, Chronic | 2 | 2012 | 1033 | 0.140 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 249 | 0.140 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 1998 | 186 | 0.140 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1997 | 130 | 0.140 |
Why?
|
| Venous Cutdown | 1 | 1996 | 5 | 0.140 |
Why?
|
| Steroids | 2 | 2013 | 936 | 0.130 |
Why?
|
| Time Factors | 17 | 2013 | 40149 | 0.130 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase Catalytic Subunits | 1 | 2016 | 12 | 0.130 |
Why?
|
| Retrospective Studies | 29 | 2013 | 81635 | 0.130 |
Why?
|
| Multivariate Analysis | 11 | 2013 | 12064 | 0.130 |
Why?
|
| Accidents | 1 | 2017 | 164 | 0.130 |
Why?
|
| Registries | 5 | 2007 | 8351 | 0.130 |
Why?
|
| Follow-Up Studies | 18 | 2018 | 39309 | 0.130 |
Why?
|
| Extracorporeal Circulation | 1 | 1996 | 182 | 0.130 |
Why?
|
| B-Lymphocytes | 11 | 1991 | 4784 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2001 | 562 | 0.130 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2016 | 85 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2001 | 614 | 0.130 |
Why?
|
| Lymphocele | 2 | 1996 | 19 | 0.130 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1996 | 284 | 0.130 |
Why?
|
| Social Class | 2 | 2018 | 2007 | 0.130 |
Why?
|
| Internship and Residency | 1 | 2016 | 5943 | 0.120 |
Why?
|
| Lymphoma | 9 | 1989 | 1900 | 0.120 |
Why?
|
| Fatigue | 3 | 2011 | 1555 | 0.120 |
Why?
|
| Short Bowel Syndrome | 1 | 1998 | 352 | 0.120 |
Why?
|
| Adolescent | 32 | 2018 | 88904 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2009 | 2306 | 0.120 |
Why?
|
| Databases, Factual | 3 | 2007 | 8066 | 0.120 |
Why?
|
| Neoplasms | 5 | 2007 | 22350 | 0.120 |
Why?
|
| Housing | 1 | 2019 | 683 | 0.120 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 1996 | 303 | 0.120 |
Why?
|
| Blood Transfusion | 7 | 2012 | 1308 | 0.110 |
Why?
|
| Liver Failure | 2 | 2011 | 252 | 0.110 |
Why?
|
| Health Care Surveys | 2 | 2018 | 2425 | 0.110 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1999 | 627 | 0.110 |
Why?
|
| Quality of Life | 8 | 2011 | 13476 | 0.110 |
Why?
|
| Activities of Daily Living | 3 | 2019 | 2429 | 0.110 |
Why?
|
| Survival Analysis | 8 | 2016 | 10100 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 1999 | 769 | 0.110 |
Why?
|
| Vascular Surgical Procedures | 1 | 2022 | 1506 | 0.110 |
Why?
|
| Lymphocyte Culture Test, Mixed | 6 | 1995 | 511 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2003 | 1595 | 0.110 |
Why?
|
| Heme Oxygenase-1 | 2 | 2012 | 364 | 0.110 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1996 | 538 | 0.110 |
Why?
|
| Capillary Permeability | 3 | 1986 | 772 | 0.100 |
Why?
|
| Treatment Outcome | 15 | 2013 | 65273 | 0.100 |
Why?
|
| Opportunistic Infections | 4 | 2010 | 376 | 0.100 |
Why?
|
| Isoantigens | 2 | 1995 | 562 | 0.100 |
Why?
|
| Aged | 32 | 2020 | 171343 | 0.100 |
Why?
|
| Hospital Costs | 1 | 1999 | 955 | 0.100 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2013 | 61 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2005 | 2817 | 0.100 |
Why?
|
| T-Lymphocytes | 9 | 1995 | 10264 | 0.100 |
Why?
|
| BK Virus | 1 | 2013 | 120 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2015 | 20708 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2005 | 3799 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2018 | 1140 | 0.100 |
Why?
|
| Immunity, Cellular | 4 | 1986 | 1560 | 0.100 |
Why?
|
| Lymphocytes | 4 | 1983 | 2605 | 0.100 |
Why?
|
| Peritoneal Neoplasms | 1 | 1998 | 706 | 0.100 |
Why?
|
| Risk Assessment | 6 | 2013 | 24295 | 0.100 |
Why?
|
| Tissue Transplantation | 1 | 2012 | 128 | 0.090 |
Why?
|
| Cadaver | 6 | 2009 | 1362 | 0.090 |
Why?
|
| Unemployment | 1 | 2013 | 211 | 0.090 |
Why?
|
| Communicable Diseases | 2 | 1997 | 872 | 0.090 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2012 | 293 | 0.090 |
Why?
|
| Organ Preservation | 1 | 2015 | 400 | 0.090 |
Why?
|
| Boston | 4 | 2012 | 9346 | 0.090 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2012 | 215 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1995 | 812 | 0.090 |
Why?
|
| Pregnancy Complications | 2 | 2004 | 2971 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2009 | 5368 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 6359 | 0.090 |
Why?
|
| Mice, SCID | 2 | 1995 | 2628 | 0.090 |
Why?
|
| Polyomavirus Infections | 1 | 2013 | 193 | 0.090 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2010 | 64 | 0.090 |
Why?
|
| Intraoperative Complications | 3 | 2012 | 1171 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 6 | 1996 | 838 | 0.090 |
Why?
|
| Mood Disorders | 3 | 2013 | 1127 | 0.090 |
Why?
|
| Primary Graft Dysfunction | 1 | 2011 | 112 | 0.080 |
Why?
|
| Curriculum | 1 | 2023 | 3783 | 0.080 |
Why?
|
| Isoantibodies | 1 | 1993 | 681 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2018 | 6329 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2019 | 2116 | 0.080 |
Why?
|
| Urinalysis | 1 | 2011 | 369 | 0.080 |
Why?
|
| Interleukin-2 | 5 | 2003 | 1895 | 0.080 |
Why?
|
| Israel | 1 | 2011 | 726 | 0.080 |
Why?
|
| Social Responsibility | 1 | 2012 | 382 | 0.080 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1989 | 89 | 0.080 |
Why?
|
| Cell Death | 2 | 2013 | 1676 | 0.080 |
Why?
|
| Educational Status | 2 | 2023 | 2510 | 0.080 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 1988 | 41 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2007 | 6214 | 0.080 |
Why?
|
| Spouses | 1 | 2011 | 286 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 7431 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 1992 | 1802 | 0.070 |
Why?
|
| Biopsy | 5 | 2004 | 6779 | 0.070 |
Why?
|
| Mandatory Testing | 1 | 2007 | 23 | 0.070 |
Why?
|
| Lupus Nephritis | 1 | 1991 | 324 | 0.070 |
Why?
|
| Regional Blood Flow | 3 | 1986 | 1478 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 3432 | 0.070 |
Why?
|
| Intestinal Volvulus | 1 | 2009 | 82 | 0.070 |
Why?
|
| Young Adult | 8 | 2018 | 59939 | 0.070 |
Why?
|
| Altruism | 1 | 2009 | 211 | 0.070 |
Why?
|
| Chemotaxis, Leukocyte | 4 | 1986 | 661 | 0.070 |
Why?
|
| Directed Tissue Donation | 1 | 2007 | 18 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2015 | 1409 | 0.070 |
Why?
|
| Ventilator Weaning | 1 | 2008 | 170 | 0.070 |
Why?
|
| Logistic Models | 5 | 2013 | 13278 | 0.070 |
Why?
|
| Speech | 1 | 2012 | 555 | 0.070 |
Why?
|
| Antiviral Agents | 2 | 1999 | 3070 | 0.070 |
Why?
|
| Lymphocyte Depletion | 1 | 1989 | 606 | 0.070 |
Why?
|
| Lymphokines | 3 | 1986 | 924 | 0.070 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 1250 | 0.070 |
Why?
|
| Child | 21 | 2016 | 80668 | 0.070 |
Why?
|
| Surgical Wound Infection | 2 | 2012 | 1547 | 0.070 |
Why?
|
| Endosonography | 1 | 2010 | 626 | 0.070 |
Why?
|
| Infectious Mononucleosis | 3 | 1988 | 133 | 0.070 |
Why?
|
| Florida | 3 | 2013 | 417 | 0.070 |
Why?
|
| History, 20th Century | 2 | 2022 | 2764 | 0.070 |
Why?
|
| Incidence | 6 | 2008 | 21525 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 3 | 2009 | 2232 | 0.060 |
Why?
|
| Anastomosis, Roux-en-Y | 2 | 2009 | 86 | 0.060 |
Why?
|
| Gallbladder Diseases | 1 | 2006 | 139 | 0.060 |
Why?
|
| Adaptation, Psychological | 2 | 2013 | 2662 | 0.060 |
Why?
|
| Abdominal Neoplasms | 2 | 1984 | 286 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2003 | 641 | 0.060 |
Why?
|
| Age Factors | 5 | 2011 | 18397 | 0.060 |
Why?
|
| Photomicrography | 1 | 2004 | 71 | 0.060 |
Why?
|
| Cyclosporins | 2 | 1988 | 216 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1992 | 1814 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 8735 | 0.060 |
Why?
|
| Animals | 23 | 2015 | 168930 | 0.060 |
Why?
|
| Linear Models | 2 | 2011 | 5874 | 0.060 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2005 | 133 | 0.060 |
Why?
|
| Health Policy | 2 | 2013 | 2698 | 0.060 |
Why?
|
| Costs and Cost Analysis | 3 | 1998 | 1667 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 2 | 1996 | 565 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 4056 | 0.050 |
Why?
|
| Hepatic Veins | 1 | 2003 | 112 | 0.050 |
Why?
|
| Glioblastoma | 1 | 1998 | 3458 | 0.050 |
Why?
|
| Mice, Inbred Strains | 4 | 1995 | 1767 | 0.050 |
Why?
|
| Algorithms | 1 | 2004 | 14072 | 0.050 |
Why?
|
| Lymph Nodes | 7 | 1990 | 3468 | 0.050 |
Why?
|
| Acyclovir | 3 | 1993 | 266 | 0.050 |
Why?
|
| Coronary Thrombosis | 1 | 2005 | 440 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2012 | 2976 | 0.050 |
Why?
|
| Hemagglutinins | 1 | 2003 | 111 | 0.050 |
Why?
|
| Ligation | 1 | 2003 | 446 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1990 | 1374 | 0.050 |
Why?
|
| Antifibrinolytic Agents | 1 | 2005 | 289 | 0.050 |
Why?
|
| HIV Infections | 3 | 2016 | 17536 | 0.050 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2002 | 141 | 0.050 |
Why?
|
| China | 1 | 2008 | 2383 | 0.050 |
Why?
|
| Graft vs Host Reaction | 1 | 1982 | 99 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2013 | 9661 | 0.050 |
Why?
|
| Intraoperative Period | 2 | 2007 | 511 | 0.050 |
Why?
|
| Hypotension | 1 | 2008 | 887 | 0.050 |
Why?
|
| Health Status | 2 | 2013 | 4087 | 0.050 |
Why?
|
| Drainage | 2 | 2002 | 1182 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 2003 | 160 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2013 | 2190 | 0.050 |
Why?
|
| Antibodies, Viral | 6 | 1990 | 3212 | 0.050 |
Why?
|
| Thrombosis | 1 | 1996 | 2953 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 2334 | 0.050 |
Why?
|
| Plasmapheresis | 2 | 1993 | 205 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2013 | 6512 | 0.050 |
Why?
|
| Brain Neoplasms | 2 | 1998 | 9101 | 0.050 |
Why?
|
| Thoracic Neoplasms | 1 | 1983 | 269 | 0.050 |
Why?
|
| Splenectomy | 1 | 2003 | 390 | 0.050 |
Why?
|
| Reimbursement Mechanisms | 1 | 2006 | 670 | 0.050 |
Why?
|
| Immune Tolerance | 3 | 2003 | 2325 | 0.050 |
Why?
|
| Guanine | 1 | 1982 | 280 | 0.040 |
Why?
|
| Severity of Illness Index | 4 | 2011 | 15908 | 0.040 |
Why?
|
| Lymphocyte Activation | 5 | 1989 | 5503 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 1885 | 0.040 |
Why?
|
| Jejunostomy | 1 | 2000 | 61 | 0.040 |
Why?
|
| Swine | 1 | 2010 | 5987 | 0.040 |
Why?
|
| Cholangiography | 1 | 2000 | 182 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2005 | 928 | 0.040 |
Why?
|
| Prednisone | 2 | 1998 | 1566 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 3 | 1995 | 9244 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2006 | 1574 | 0.040 |
Why?
|
| History, 19th Century | 1 | 2022 | 714 | 0.040 |
Why?
|
| Safety | 1 | 2004 | 1157 | 0.040 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2000 | 108 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2010 | 2101 | 0.040 |
Why?
|
| Lymphatic Diseases | 1 | 1981 | 318 | 0.040 |
Why?
|
| Immunization, Passive | 3 | 1992 | 618 | 0.040 |
Why?
|
| Europe | 1 | 2006 | 3430 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 8045 | 0.040 |
Why?
|
| Mental Health | 1 | 2013 | 3270 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2005 | 1350 | 0.040 |
Why?
|
| DNA, Satellite | 1 | 1999 | 67 | 0.040 |
Why?
|
| Clone Cells | 3 | 1989 | 1670 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1991 | 2160 | 0.040 |
Why?
|
| Mice, Inbred DBA | 2 | 1995 | 624 | 0.040 |
Why?
|
| Postoperative Care | 3 | 2013 | 1480 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 6307 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 3266 | 0.040 |
Why?
|
| Caregivers | 1 | 2011 | 2303 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2005 | 1610 | 0.040 |
Why?
|
| Recurrence | 3 | 2013 | 8507 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2012 | 6259 | 0.040 |
Why?
|
| Morbidity | 2 | 2001 | 1754 | 0.040 |
Why?
|
| Biliary Tract | 1 | 1999 | 136 | 0.040 |
Why?
|
| Health Behavior | 1 | 2010 | 2649 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2011 | 10445 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 2005 | 896 | 0.040 |
Why?
|
| Substance-Related Disorders | 2 | 2013 | 4421 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 4853 | 0.040 |
Why?
|
| Transaminases | 1 | 1998 | 198 | 0.040 |
Why?
|
| Health Promotion | 1 | 2010 | 2209 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2012 | 6550 | 0.040 |
Why?
|
| Spleen | 1 | 1983 | 2295 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2004 | 1069 | 0.040 |
Why?
|
| Complement System Proteins | 2 | 1991 | 738 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2011 | 3230 | 0.030 |
Why?
|
| Mice | 15 | 2013 | 81889 | 0.030 |
Why?
|
| Gastric Bypass | 1 | 2005 | 820 | 0.030 |
Why?
|
| Cholangitis, Sclerosing | 1 | 1999 | 179 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2003 | 1437 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 1999 | 784 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 2004 | 1271 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 1995 | 2839 | 0.030 |
Why?
|
| Rabbits | 2 | 2013 | 4752 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 1996 | 1697 | 0.030 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 6962 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 4282 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1996 | 529 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 6 | 2013 | 22352 | 0.030 |
Why?
|
| Pregnancy | 4 | 2008 | 30237 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2011 | 4527 | 0.030 |
Why?
|
| Radiography | 4 | 2005 | 6968 | 0.030 |
Why?
|
| Fatty Liver | 2 | 1993 | 810 | 0.030 |
Why?
|
| Major Histocompatibility Complex | 1 | 1998 | 880 | 0.030 |
Why?
|
| Reproducibility of Results | 5 | 2011 | 20144 | 0.030 |
Why?
|
| Pilot Projects | 2 | 1999 | 8728 | 0.030 |
Why?
|
| Cell Communication | 1 | 1982 | 1660 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 9525 | 0.030 |
Why?
|
| Celiac Disease | 1 | 2002 | 821 | 0.030 |
Why?
|
| Infant | 8 | 2009 | 36461 | 0.030 |
Why?
|
| Pheochromocytoma | 1 | 1996 | 327 | 0.030 |
Why?
|
| Child, Preschool | 9 | 2009 | 42577 | 0.030 |
Why?
|
| H-2 Antigens | 2 | 1992 | 359 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 2005 | 12985 | 0.030 |
Why?
|
| Laparoscopy | 1 | 2005 | 2039 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 1998 | 661 | 0.030 |
Why?
|
| Pediatrics | 1 | 2008 | 3614 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 1995 | 527 | 0.030 |
Why?
|
| Viral Load | 2 | 2012 | 3385 | 0.030 |
Why?
|
| Vascular Patency | 1 | 1996 | 915 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 1995 | 5890 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1994 | 347 | 0.030 |
Why?
|
| Blood Group Incompatibility | 1 | 1993 | 134 | 0.030 |
Why?
|
| Research Design | 1 | 2009 | 6207 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2001 | 3552 | 0.030 |
Why?
|
| Virus Replication | 2 | 1995 | 2457 | 0.030 |
Why?
|
| Socioeconomic Factors | 3 | 2013 | 7841 | 0.030 |
Why?
|
| Pancreatectomy | 2 | 2009 | 825 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2009 | 3446 | 0.030 |
Why?
|
| Hyperplasia | 2 | 2005 | 1150 | 0.020 |
Why?
|
| Intestine, Small | 1 | 1998 | 1217 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2005 | 2596 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2009 | 26389 | 0.020 |
Why?
|
| Histocompatibility | 1 | 1993 | 327 | 0.020 |
Why?
|
| Prevalence | 1 | 2009 | 15835 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 10384 | 0.020 |
Why?
|
| Hepacivirus | 1 | 1999 | 1343 | 0.020 |
Why?
|
| Cohort Studies | 5 | 2016 | 41710 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1998 | 949 | 0.020 |
Why?
|
| Necrosis | 1 | 1996 | 1616 | 0.020 |
Why?
|
| RNA, Viral | 2 | 1999 | 2867 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 1996 | 1615 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 14652 | 0.020 |
Why?
|
| Anastomotic Leak | 1 | 2012 | 170 | 0.020 |
Why?
|
| Insulin | 1 | 2005 | 6608 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 1996 | 2846 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1995 | 1442 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 1992 | 527 | 0.020 |
Why?
|
| Antibody Specificity | 2 | 1991 | 1062 | 0.020 |
Why?
|
| Genes, Viral | 2 | 1981 | 654 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2013 | 608 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2007 | 9404 | 0.020 |
Why?
|
| Obesity | 2 | 2010 | 13090 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 1991 | 340 | 0.020 |
Why?
|
| Outpatients | 1 | 1998 | 1596 | 0.020 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 1990 | 111 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2013 | 1587 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2011 | 268 | 0.020 |
Why?
|
| Predictive Value of Tests | 4 | 2012 | 15416 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 1998 | 2391 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2016 | 2659 | 0.020 |
Why?
|
| Pancreas | 2 | 2005 | 1698 | 0.020 |
Why?
|
| Antibody Formation | 1 | 1994 | 1392 | 0.020 |
Why?
|
| Ricin | 1 | 1989 | 70 | 0.020 |
Why?
|
| Glomerulonephritis | 1 | 1991 | 333 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1993 | 668 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 2470 | 0.020 |
Why?
|
| Affective Symptoms | 1 | 2011 | 418 | 0.020 |
Why?
|
| Hepatic Encephalopathy | 1 | 1990 | 143 | 0.020 |
Why?
|
| Capsid | 2 | 1981 | 435 | 0.020 |
Why?
|
| Attitude to Death | 1 | 2011 | 400 | 0.020 |
Why?
|
| Immunotoxins | 1 | 1989 | 175 | 0.020 |
Why?
|
| Virus Diseases | 1 | 1994 | 720 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2010 | 327 | 0.020 |
Why?
|
| Equipment Design | 1 | 1996 | 3487 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1995 | 1362 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 1991 | 1352 | 0.020 |
Why?
|
| Thymectomy | 1 | 1989 | 200 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2016 | 1609 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 811 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2013 | 1469 | 0.020 |
Why?
|
| Mycophenolic Acid | 1 | 2009 | 349 | 0.020 |
Why?
|
| Culture Media | 2 | 1986 | 893 | 0.020 |
Why?
|
| Length of Stay | 1 | 2001 | 6490 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2010 | 663 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 12534 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1988 | 512 | 0.020 |
Why?
|
| Acute Disease | 3 | 1993 | 7241 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1985 | 1305 | 0.020 |
Why?
|
| Burkitt Lymphoma | 1 | 1989 | 338 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 1988 | 454 | 0.020 |
Why?
|
| Inpatients | 1 | 1998 | 2565 | 0.020 |
Why?
|
| Bradykinin | 1 | 1986 | 205 | 0.020 |
Why?
|
| Proteinuria | 1 | 2009 | 613 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2011 | 642 | 0.020 |
Why?
|
| Erythropoietin | 1 | 1991 | 718 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1994 | 1390 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 617 | 0.020 |
Why?
|
| Dumping Syndrome | 1 | 2005 | 22 | 0.020 |
Why?
|
| Prospective Studies | 5 | 2012 | 54871 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4570 | 0.020 |
Why?
|
| Brain Death | 1 | 2009 | 360 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1996 | 4188 | 0.020 |
Why?
|
| Diazoxide | 1 | 2005 | 52 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1998 | 10745 | 0.020 |
Why?
|
| Albuminuria | 1 | 2009 | 659 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 3 | 1983 | 6222 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 1990 | 754 | 0.020 |
Why?
|
| Antigens, Viral, Tumor | 1 | 1985 | 153 | 0.020 |
Why?
|
| Cross-Sectional Studies | 4 | 2010 | 26310 | 0.020 |
Why?
|
| Histamine | 1 | 1986 | 496 | 0.010 |
Why?
|
| Collagen | 1 | 2013 | 2635 | 0.010 |
Why?
|
| Models, Animal | 1 | 2011 | 2121 | 0.010 |
Why?
|
| Octreotide | 1 | 2005 | 157 | 0.010 |
Why?
|
| JC Virus | 1 | 2005 | 87 | 0.010 |
Why?
|
| Diet Therapy | 1 | 2005 | 149 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 2586 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2007 | 1180 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2010 | 36567 | 0.010 |
Why?
|
| Ataxia Telangiectasia | 1 | 1985 | 107 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2003 | 5861 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1989 | 1824 | 0.010 |
Why?
|
| Indium | 1 | 1983 | 47 | 0.010 |
Why?
|
| Urethane | 1 | 1983 | 37 | 0.010 |
Why?
|
| Inflammation | 2 | 1984 | 10860 | 0.010 |
Why?
|
| Duodenum | 1 | 1987 | 495 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2007 | 779 | 0.010 |
Why?
|
| Immunization | 2 | 1988 | 1218 | 0.010 |
Why?
|
| Polysomnography | 1 | 2010 | 1868 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2018 | 5091 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2011 | 2926 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1986 | 1251 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2011 | 2021 | 0.010 |
Why?
|
| Skin | 2 | 1989 | 4499 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 1989 | 18984 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 2704 | 0.010 |
Why?
|
| Immunoglobulin M | 2 | 1990 | 1527 | 0.010 |
Why?
|
| Serotonin | 1 | 1986 | 1045 | 0.010 |
Why?
|
| Age Distribution | 1 | 2007 | 2869 | 0.010 |
Why?
|
| Radioisotopes | 1 | 1983 | 509 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2005 | 59550 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1997 | 4747 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 4891 | 0.010 |
Why?
|
| Reference Values | 1 | 1989 | 4913 | 0.010 |
Why?
|
| Preoperative Care | 2 | 1988 | 2253 | 0.010 |
Why?
|
| Heart Transplantation | 3 | 1994 | 3306 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1981 | 212 | 0.010 |
Why?
|
| Antigens, Ly | 1 | 1982 | 297 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1986 | 975 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 4045 | 0.010 |
Why?
|
| Massachusetts | 1 | 2013 | 8891 | 0.010 |
Why?
|
| Body Weight | 1 | 2011 | 4626 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2012 | 3077 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 2008 | 1359 | 0.010 |
Why?
|
| Thymus Gland | 1 | 1985 | 1260 | 0.010 |
Why?
|
| Genomics | 1 | 2016 | 5923 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 8621 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1992 | 4410 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 865 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1988 | 3158 | 0.010 |
Why?
|
| Bronchitis | 1 | 1980 | 193 | 0.010 |
Why?
|
| Immunity | 1 | 1985 | 1002 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 13485 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 3485 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2002 | 992 | 0.010 |
Why?
|
| Pharynx | 1 | 1981 | 436 | 0.010 |
Why?
|
| Sepsis | 1 | 2012 | 2604 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1983 | 1263 | 0.010 |
Why?
|
| Cell Count | 1 | 1982 | 1826 | 0.010 |
Why?
|
| Brain | 1 | 2005 | 27159 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1981 | 548 | 0.010 |
Why?
|
| Health Surveys | 1 | 2007 | 4055 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1985 | 2730 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1981 | 995 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 1999 | 630 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2005 | 2060 | 0.010 |
Why?
|
| Pain | 1 | 2011 | 5098 | 0.010 |
Why?
|
| Chlamydia Infections | 1 | 1980 | 365 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2007 | 2519 | 0.010 |
Why?
|
| Cytokines | 1 | 2011 | 7438 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 1980 | 505 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 14471 | 0.010 |
Why?
|
| Lymphatic System | 1 | 1977 | 250 | 0.010 |
Why?
|
| Ganciclovir | 1 | 1996 | 256 | 0.010 |
Why?
|
| Genotype | 1 | 1990 | 13036 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1982 | 1962 | 0.010 |
Why?
|
| Immunoglobulin G | 2 | 1990 | 4559 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2009 | 6422 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 6850 | 0.010 |
Why?
|
| Kinetics | 1 | 1982 | 6287 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1994 | 361 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 22248 | 0.010 |
Why?
|
| Cell Movement | 2 | 1983 | 5199 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2010 | 13050 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2006 | 3283 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2008 | 8533 | 0.010 |
Why?
|
| DNA | 1 | 1985 | 7208 | 0.010 |
Why?
|
| Risk | 1 | 1983 | 9602 | 0.010 |
Why?
|
| Physicians | 1 | 2009 | 4591 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 30213 | 0.010 |
Why?
|
| Herpes Simplex | 1 | 1994 | 470 | 0.010 |
Why?
|
| Colon | 1 | 1999 | 1797 | 0.010 |
Why?
|
| Ascites | 1 | 1991 | 336 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1991 | 6507 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 1993 | 8540 | 0.010 |
Why?
|
| Plateletpheresis | 1 | 1988 | 39 | 0.000 |
Why?
|
| Diabetes Mellitus | 1 | 1987 | 5887 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1996 | 1794 | 0.000 |
Why?
|
| Pneumonia | 1 | 1980 | 2159 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2011 | 23619 | 0.000 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1990 | 587 | 0.000 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 1987 | 99 | 0.000 |
Why?
|
| HLA Antigens | 1 | 1991 | 1339 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1993 | 4018 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 11061 | 0.000 |
Why?
|
| Plasma | 1 | 1988 | 583 | 0.000 |
Why?
|
| Leukocyte Transfusion | 1 | 1984 | 58 | 0.000 |
Why?
|
| Organ Specificity | 1 | 1988 | 1966 | 0.000 |
Why?
|
| Erythrocyte Transfusion | 1 | 1988 | 574 | 0.000 |
Why?
|
| Porifera | 1 | 1983 | 32 | 0.000 |
Why?
|
| Caseins | 1 | 1983 | 105 | 0.000 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1984 | 306 | 0.000 |
Why?
|
| Serum Albumin, Bovine | 1 | 1983 | 319 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 15657 | 0.000 |
Why?
|
| Desensitization, Immunologic | 1 | 1987 | 546 | 0.000 |
Why?
|
| Sex Factors | 1 | 1994 | 10619 | 0.000 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1984 | 335 | 0.000 |
Why?
|
| Karyotyping | 1 | 1981 | 1176 | 0.000 |
Why?
|
| Chlamydia trachomatis | 1 | 1980 | 239 | 0.000 |
Why?
|
| Cell Separation | 1 | 1983 | 1718 | 0.000 |
Why?
|
| Cattle | 1 | 1983 | 3815 | 0.000 |
Why?
|
| Lymph | 1 | 1977 | 78 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1981 | 1505 | 0.000 |
Why?
|
| Thoracic Duct | 1 | 1977 | 71 | 0.000 |
Why?
|
| Lymphography | 1 | 1977 | 189 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1984 | 3609 | 0.000 |
Why?
|
| Chromosome Aberrations | 1 | 1981 | 1776 | 0.000 |
Why?
|
| DNA, Viral | 1 | 1981 | 2201 | 0.000 |
Why?
|
| Specimen Handling | 1 | 1977 | 706 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1981 | 3641 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1984 | 2534 | 0.000 |
Why?
|
| Catheterization | 1 | 1977 | 1429 | 0.000 |
Why?
|
| Macrophages | 1 | 1984 | 5783 | 0.000 |
Why?
|
| Models, Biological | 1 | 1984 | 9461 | 0.000 |
Why?
|
| Phenotype | 1 | 1983 | 16724 | 0.000 |
Why?
|
| Lung | 1 | 1980 | 10067 | 0.000 |
Why?
|